The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Archive of Articles From The Treatment Action Group (TAG)

2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | Articles/Reports | En Español

The Treatment Action Group (TAG) logo


from the Treatment Action Group (TAG):
A monthly paper of research and policy


Spring 2016

  1. Greed and the Necessity for Regulation
    The story of U.S. drug pricing run amok isn't just about corporate arrogance and avarice -- it is also about government permissiveness and inaction.
  2. PrEP Pricing Problems
    A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified -- cost shouldn't be one of them.
  3. The Low Cost of Universal Access
    Generic treatments for HIV, viral hepatitis, and cancer can be affordably -- and profitably -- mass-produced for broad, unobstructed availability.


Fall 2015

  1. The Challenge of Defining HIV Remission
    Supportive regulatory guidance for cure research requires a clear understanding of all possible outcomes, including remission.
  2. PrEP: The Pathway to Global Access
    Regulatory filing and review delays keep Truvada as pre-exposure prophylaxis out of reach of those who need it most.

Spring 2015

  1. Ending the HIV Epidemic in New York State
    Not only is it the right thing to do for the health of New Yorkers, but a new analysis demonstrates that it is also cost-effective.
  2. Toward an Ambitious National HIV/AIDS Strategy
    We won't end HIV as an epidemic with anemic goals, delayed surveillance data, feeble support of state policies and resource needs and an inadequate implementation science agenda.
  3. An HIV Cure and Vaccine Within the Next 15 Years?
    Optimism is not without merit, but the science remains incredibly fragile.
  4. C U L8tr: Hepatitis C Eradication
    Hepatitis C is now curable. Now all we need is surveillance to monitor it, global funding to fight it and targets set to address it.


Fall 2014

  1. Generic Drug Registration, Licensing and�a Trip to Gilead's Islands

Spring 2014

  1. Forgotten Negatives: The Limits of Treatment as Prevention
    The CDC's High-Impact Prevention strategy takes aim at the stubborn HIV incidence rate in the United States. The only problem: it doesn't include an ambitious plan for those at risk for the virus.
  2. The White House's Fuzzy Math
    An Office of National AIDS Policy progress report obscures the state of the domestic U.S. HIV/AIDS response.
  3. Marketplace Menaces: Discriminatory Practices by the ACA's Qualified Health Plans
    Advocates scramble to stay ahead of coverage rejections, formulary concerns and exorbitant out-of-pocket expenses facing people living with HIV.
  4. Better Late Than Never: Efavirenz Dose Optimization
    After a study suggests that we've been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles.
  5. Punked by Pharma: Public Funds for Private Products
    Tax dollars are making it easier for the drug and diagnostics industry to develop and market essential TB products. Is the public getting a fair return on its investment?
  6. Fool's Errand: The Sloppy Science of the MDR-TB STREAM Trial
    Confirming the efficacy and safety of bedaquiline-inclusive regimens is a priority. Comparing them to unvalidated MDR-TB drug combinations in the planned STREAM study is not the way to go about it.


Fall 2013
To read PDF, click here

  1. A Commitment to the HIV Continuum of Care
    President Obama orders multiagency cooperation to achieve National HIV/AIDS Strategy goals, but without required funding commitment.
  2. Engagement in Care: A Final Frontier of HIV Medicine
    Getting more HIV-positive people linked to and retained in care requires innovation and research.
  3. Toward a Plan to End AIDS in New York State
    A coalition of community groups push to end AIDS at the epicenter of the U.S. epidemic.
  4. HIV Prevention Is the Surest Way to Fight AIDS
    ACT UP/NY demands Department of Health accountability at the epicenter of the U.S. epidemic and commits to reinvigorate the national prevention agenda.
  5. TAG's Commitment to HIV Prevention
  6. Emerging Regulatory Issues in HIV Cure Research
    The science of discovery comes with ethical challenges in human clinical trials.

Spring 2013
To read PDF, click here

  1. Ryan White at a Crossroads: Preparing to Defend and Reshape a Still-Critical Program
  2. The "G" Word: Gilead's Greed Gives Rise to a Slew of Advocacy Priorities
  3. Razing the House of Cards: The Discovery of HAART and the Push for Evidence-Based HIV Treatment
  4. Preparing for Generics: The Push for Affordable HIV Treatment Doesn't End With Patent Expirations
  5. Undetectable Is Not Always Enough: Immunologic Nonresponders Face Increased Risk of Illness, but Lack Therapeutic Options


Fall 2012
To read PDF, click here

  1. On a Darkling Plain -- The Years of Despair
    Before the discovery of HAART.
  2. Only Stronger U.S. Leadership Can End the AIDS Epidemic
    Existing treatment and prevention techniques could prevent millions of new HIV infections and deaths from AIDS -- but only if Obama sustains funding.

Spring 2012
To read PDF, click here

  1. TAG at 20: Early Campaigns
    Reforming NIH AIDS research, boosting the budget and revitalizing the basic science of HIV infection.
  2. The Odyssey of Therapeutic Vaccines for HIV
  3. What You Don't Know, You Can Sell
    Merck's cavalier attitude towards the welfare of HIV/HCV coinfected patients.
  4. Does Obama's 2013 Budget Herald the End of PEPFAR?
    Devastating funding proposal undermines the global fight against AIDS.


Fall 2011
To read PDF, click here

  1. A Golden Decade of Antiretroviral Drug Development
    Success rate for new ARVs entering phases II-III surpassed 32% from 2003-2011; U.S. ADAP prescribing practices closely match recent ARV guidelines.
    By Polly Clayden and Mark Harrington
  2. Cure Research Momentum Accelerates
    By Richard Jefferys
  3. What We Need to Cure AIDS?
    By Mark Harrington

Summer 2011
To read PDF, click here

  1. Julie Davids Reflects on CHAMP and the Future of HIV Prevention Justice
    Interview with veteran HIV prevention and social justice activist Julie Davids.
  2. Moving an Exciting New TB Diagnostic From Policy to Practice
    By Javid Syed
  3. Vaccine Breakthrough Comes With Caveats
    By Richard Jefferys
  4. Clinical Trials Will Play a Vital Role in Charting the Path to an HIV Cure

Winter 2011
To read PDF, click here

  1. The Past, Present and Future of HIV Microbicide Research Advocacy
    An interview with Polly Harrison, founder of the Alliance for Microbicide Development.
  2. The First New Tuberculosis Drug in Decades: Promise and Challenges
  3. HIV/AIDS Clinical Trials Network to Take on New Research Priorities Under Severe Funding Constraints
    By Coco Jervis
  4. Microbicide Field Wrestles With the Implications of Success -- an Update


Autumn 2010
To read PDF, click here

  1. Reinvigorating the Search for a Cure
    By Richard Jefferys
  2. Microbicide Field Wrestles With the Implications of Success
    By Richard Jefferys and Scott Morgan
  3. Access to Hepatitis C Treatment: A Global Movement Gains Momentum
    By Tracy Swan
  4. Deadly Economics Threaten Progress to Global Health Goals
    By Coco Jervis and Sue Perez
  5. National Institutes of Health Donates Protease Inhibitor Patent to UNITAID Medicines Patent Pool
    By Mark Harrington
  6. AIDS Drug Assistance Program in Crisis

Summer 2010
To read PDF, click here

  1. Inflammatory Debate Over When to Start
    By Richard Jefferys
  2. A New Start for an Old Movement
    The making of the HIV Research Catalyst Forum.
    By Lei Chou and Coco Jervis
  3. Can More People Be Put on ART Without Increased Cost?
    By Scott Morgan
  4. What U.S. Health Care Reform Means for People With HIV
    Slow implementation for needed changes.
    By Sue Perez and Coco Jervis

Winter 2010
To read PDF, click here

  1. World Health Organization HIV Treatment Guidelines Evolve
    Safer and more effective drug combinations included in new guidelines.
    By Mark Harrington
  2. NIAID Workshop: Elimination of HIV Reservoirs
    By Richard Jefferys
  3. Two New Classes of TB Drugs -- the First in 40 Years -- Advance Through Phase II Studies
    After 40 years of scientific stagnation, it is beginning to be an exciting time in tuberculosis treatment research.
    By Claire Wingfield
  4. As With HIV Treatment, Botswana Leads the Way With TB Prevention
    BOTUSA study strongly supports continuous preventive IPT for people with HIV.
    By Javid Syed
  5. TAG Goes to Cuba
    Cuba boasts model health outcomes but at what costs to human rights?
    By Coco Jervis
  6. Do The Right Thing
    Eliminating racial disparities in viral hepatitis drug development.
    By Lei Chou and Tracy Swan, presented at HEP DART 2009
  7. President Obama's Disappointing 2011 Budget Presents Sharp Gap Between Needs and Funds Available
    Negligible increases for AIDS, TB, viral hepatitis treatment and research.
    By Sue Perez
  8. Tools for TB Advocacy


Summer 2009
To read PDF, click here

  1. AIDS Funding Backlash
    A conversation with Sue Perez and Gregg Gonsalves.
    By Scott W. Morgan
  2. The HIV Entry Ban: What's Next?
    A talk with Nancy Ordover.
    By Bob Huff
  3. A Long-Term Survivor
    The pioneering MACS cohort.
    By Gregg Gonsalves
  4. State AIDS Drug Assistance Program (ADAP) Hepatitis Coverage (PDF)
  5. Two New TAG Publications
    Research funding gaps revealed

Winter 2008/2009
To read PDF, click here

  1. TAG Sponsors "Cure Meeting"
  2. TAG Remembers Paul Newman


Summer 2008
To read PDF, click here

  1. Sixteen Radical Steps to End the AIDS Epidemic
    By Mark Harrington
  2. Notes on the 2008 International AIDS Conference
    By Bob Huff
  3. Meet the Activists: Battling the TB/HIV Epidemic Through Community Action
  4. A Chimpanzee Tale: Why Are They Resistant to AIDS?
    By Richard Jefferys
  5. The Shrinking of PAVE100: Large-Scale Vaccine Trial Nixed
    By Richard Jefferys

Winter 2008
To read PDF, click here

  1. Merck HIV Vaccine Trial Results: Hopes Dim for Struggling Field
    By Richard Jefferys
  2. Action Needed Against TB/HIV and the MDR- and XDR-TB Crisis
    By Theo Smart and Javid Syed
  3. Palm Project Interviews: A Talk With Steven Deeks
    By Richard Jefferys
  4. "Cure for AIDS" Finds New Life Among Scientists and Activists


September 2007
To read PDF, click here

  1. Rapidly Progressing Hepatitis C in New York Gay Men
    By Tracy Swan
  2. The Sitges Statement on HCV Drug Development
  3. Studying New Drugs for HCV: Excerpts From the FDA Hearings
    By Bob Huff
  4. Worldwide Antiretroviral Drug Sales 2006
  5. Faster TB Test for Resource-Limited Settings
    By Theo Smart
  6. Basic Research is a Government Responsibility
    By Robert Siliciano, M.D., Ph.D.
  7. Immune Activation in HIV Infection: More Than Just Markers
    By Richard Jefferys


December 2006
To read PDF, click here

  1. Activist Chides TB Congress for Complacency in Facing Drug Resistance
    By Theo Smart
  2. Tuberculosis Research & Development: A Critical Analysis
  3. How We Treat TB Today: A Talk With Gavin Churchyard
    By Mark Harrington
  4. TB Transmission in Healthcare Settings
    By Theo Smart
  5. Gut Reactions
    By Richard Jefferys
  6. Update: Leaking LPS
  7. In Brief
  8. GRACE Under Pressure
    By Rob Camp
  9. Editorial: What's Next? Leadership Lacking in Move From 3x5 to Universal Access
    By Mark Harrington

April 2006
To read PDF, click here

  1. SMART Stops Stopping
    By Richard Jefferys
  2. HCV at CROI: Growing Chasm Between Bench and Bedside
    By Tracy Swan
  3. Overlapping Epidemics: TB, HIV and Viral Hepatitis
    By Tracy Swan
  4. TB Diagnostics: A Crisis for People Living With HIV/AIDS Worldwide
    By Javid Syed
  5. Co-Receptor Conundrum
    By Richard Jefferys


January 2005
To read PDF, click here

  1. Dismal Science: Squandering Public Goodwill and Scarce Research Funds to Boot -- But to What End?
    By Richard Jefferys
  2. Well, How Did We Get Here? A Timeline for the Initiation of the RV144 Prime-Boost Trial
    By Richard Jefferys
  3. Late 2004 Changes to Federal (DHHS) Treatment Guidelines
  4. Caveat Lector, the Sequel: Tangle of Interests and Disclosure Omissions Cracks Authors' Case for Early, Aggressive Treatment
    By Mike Barr
  5. Taylor-ed Treatment: Brown University Clinician Leads the Way in Providing Competent Care to Coinfected Injectors
    By Tracy Swan
  6. Letters to the Editor


December 2004
To read PDF, click here

  1. Truv�nadu: Does Gilead's Famed 903 Study Really Show You What They Tell You It Shows?
    By Steven Miles, M.D.
  2. Cell Therapy aka Therapeutic "Vaccine" Surprise Announcement for World AIDS Day
    By Mike Barr
  3. Project Inform's IX IRTT: Why the Tap 'n' Drainers Have Always Been Wrong; Plus, a New Theory About MDR HIV
    By Richard Jefferys
  4. Dogs and Ponies: Mixed Results (and Lots of Diarrhea) for the Tipranavir Studies; Plus Salvage Study Designs for JNJ/Tibotec's PI and Non-Nuke
    By Rob Camp and Mike Barr
  5. Who Provides You With Up-to-Date Treatment Information? Popular Treatment Information Resources for Doctors and Patients -- and Their Reliance on Pharmaceutical Largesse

October 2004

  1. Treble Damages: Vaccine Scientists Struggle to Come to Grips With the Field's "Berlin"
    By Richard Jefferys
  2. Little Leap: Gilead 2-in-1 Opens Door to Impending One-Pill Triple Combo
    By Rob Camp
  3. Note to Readers/Aviso a Nuestros Lectores en Español
  4. Now Available at the TAG Web Site

September 2004
To read PDF, click here

  1. The Irony of Bangkok: How to Get 6 Million Poor People on Antiretroviral Therapy -- and 1 Million Rich People Off
  2. The Agony of Bangkok: Thai Activist Exhorts Conference Crowd to Stand Firm Against U.S. Patent Regime and "Masks of Fake Concern"
    By Paisan Suwannawong
  3. A Call to Arms: Veteran NEJM Editor Takes on Big Pharma as No One Before; Calls for Sweeping Reforms

August 2004
To read PDF, click here

  1. TDM, Stat!: More Mixes Nixed By Concentration Preoccupations
    By Yasmin Halima and Rob Camp
  2. Continuous HAART and the Law of Diminishing Returns: French Researchers Question Benefit of Lifelong Antiretroviral Treatment
  3. Breaking the Silence, v2: Treatment Advocates Strategize At TAG's 2nd Annual International TB/HIV Workshop

July 2004
To read PDF, click here

  1. One Step Forward: Merck Vaccine Moves Forward With Efficacy Trial, While Special Committee Tries to Salvage Thai Study
  2. Checkmate: French African Study Offers Critical Challenge To Generics Obstructionists
    By Mike Barr
  3. Stern Words For Pfizer

June 2004
To read PDF, click here

  1. Goodnight, Gracie! Quirky PK of BI's Tipranavir May Confine Its Use to Limited Rescue Role
    By Rob Camp
  2. Public Unhealth: Expert Panel's Decision to Recommend Against Routine HCV Screening Draws Community Ire
    By Tracy Swan
  3. Response to U.S. Preventative Services Task Force Recommendations on Screening for HCV Infection

May 2004
To read PDF, click here

  1. Trust Busting: Abbott, Trimeris/Roche Pricing Decisions Rekindle Old R&D Cost Questions
  2. Letters to the Editor
  3. Pharmacy by Fiat: Little-Noticed Ban of Little-Used Drug Triggers Little-Known Investigation
    By Dr. Paul C. Bellman

April 2004
To read PDF, click here

  1. Peg Elation: XI CROI, Stage for Results of Three Large HCV Treatment Trials
    By Tracy Swan
  2. Where's My Pipeline? Vicissitudes of Medicine and Marketing Take Toll on Me-Too Line Up
    By Rob Camp

March 2004
To read PDF, click here

  1. Fuzeon Fizzles: Bungled T-20 Launch Claims Its First Casualties, as Losses Spread
    By Mike Barr
  2. Crux as Crock: One Shot Immune-Based Therapy Would Be Patient Dream -- and Pharma's Dread
    Interview with Richard Jefferys
  3. Seven (Minus 4, Plus 3) Agents to Fix Your Gaze On
    By Rob Camp

February 2004
To read PDF, click here

  1. Shot in the Dark: Against the Odds, Immune-Based Therapies for HIV Slog Along
    By Richard Jefferys
  2. Blockbusters Beckon: Proliferation of Polymerase Inhibitors and Other Tales From the HCV Crypt
    By Tracy Swan

January 2004
To read PDF, click here

  1. Heart of the Matter: To Date, Global Fund Offers Hype and Hope -- But Little Else -- to Majority of Those in Need
    By Richard Stern
  2. For Thousands of PWHIVs, Scale Up = Death
    By Richard Stern
  3. World AIDS Day in Bolivia: Activists Interrupt Vice Minister of Health at Inauguration Ceremony
  4. Holding Court: Activist Meeting With FDA Drugs Division Sets Broad Agenda for Change
    By Rob Camp


December 2003
To read PDF, click here

  1. Give 'em Hell, Hogan: Pointers and Prerogatives From and for the Unrepentant Problem Patient
    By Carlton Hogan
  2. TAG 2003: The Year at a Glance
  3. Past as Prologue: Expediency, Cost-Cutting Trump Science in Peg-Intron Clinical Development Plan
    By Tracy Swan

November 2003
To read PDF, click here

  1. Lexiva Launch: Glaxo Makes Aggressive Push Into Protease Market With New and Improved Amprenavir
    By Rob Camp and Heidi Nass
  2. Scrambling the Code: What a Difference a Nucleotide Makes -- Plus IL-15's Role Is STI Outcomes
    By Richard Jefferys

October 2003
To read PDF, click here

  1. The Diabolic Science: VaxGen's Claims of Vaccine Efficacy Evanesce in Autumn's Last Light
    By Richard Jefferys
  2. Medi Gap: Congressional Juggling of Medicare Drug Coverage Leaves Many in the Lurch
  3. Letter to President Bush
    By William E. Arnold, Mark Harrington and A. Cornelius Baker

September 2003
To read PDF, click here

  1. Rx Americas: Antiretroviral Therapy in Latin America: North of the Southern Cone, a Good Plan Is Hard to Find
    By Richard Stern
  2. Tragical Realism: Treatment Coverage for Selected Countries
    By Richard Stern
  3. ACTing UP for Treatment Access in Latin America
    By Richard Stern
  4. Second Shoe: Doha Dance Has Health Ministries Scheming to Provide Care -- Without Pissing Off Uncle Sam
    By Anne Christine d'Adesky

July 2003
To read PDF, click here

  1. Separated at Birth
  2. Saturation Point: Latest Licensure Breaks Records for Ho-Hum Reception, yet What Exactly Is There to Be Excited About?
    By Rob Camp
  3. Wheat From Chaff: Take-No-Prisoners Tack on TAG Pipeline Report Snubs Host of Drab Wannabes; Cozies up to Fevered Few

June 2003
To read PDF, click here

May 2003
To read PDF, click here

  1. Escape From the CTLs: Acute Rx Paradigm Dealt Heavy Blow, While Neutralizing Antibodies Stage a Comeback
    By Richard Jefferys
  2. End of an Era: Can a Conference (and an Activist) Outlive Its Utility? A Moment of Unabashed Navel Gazing
    By David Barr
  3. TAG at Ten: The Year 2002

April 2003
To read PDF, click here

  1. Full Count: Having Sired Twin Failures Hivid and Invirase, Roche Tempts Fate With High Profile T-20 Launch
    By Rob Camp and Matt Sharp
  2. Tipping Point: MSF, Oxfam Redefine the Possible, and Y2K Activist Trek to Durban Marks a Watershed
    By David Barr
  3. TAG at Ten: The Year 2001

March 2003
To read PDF, click here

  1. Magic With Numbers: AIDSVAX Arbitrary and Post-Hoc Subset Analysis, Up Close
  2. Under Icebergs' Tip: Tissue T-Cell Analysis Represents Renewed Challenge to "Tap and Drain" Orthodoxy
    By Richard Jefferys
  3. Yin and Yang: Yokohama, Vancouver, Twin Pacific Ports, Serve as Polar Opposites for Scientific Advances
    By David Barr
  4. Consensus Statement: AIDSVAX Fails to Protect; VaxGen's Claims of Efficacy in Black and Asian Participants Are Misleading and Premature
  5. TAG at Ten: The Year 2000

January/February 2003
To read PDF, click here

  1. Pushing the Envelope: Critical Issues From TAG's Forthcoming HCV/HIV Co-Infection Report and Analysis
    By Tracy Swan
  2. Necessary Diversions: The Boston AIDS Conference That Never Was -- And Other Grim Tales
    By David Barr
  3. TAG at Ten: The Year 1999


December 2002
To read PDF, click here

  1. Enemies at the Gate: Storming Montréal's Palais de Congrès, and Makeshift Battle Stations in Fortress San Francisco
    By David Barr
  2. TAG at Ten: The Year 1998
  3. Jabberwocky: Feel Good, "Why Can't We Just All Be Friends?" Executive Reunion Ends in Promises Aplenty
    By Mark Harrington

November 2002
To read PDF, click here

  1. Altered States: Nattering Nabobs' Noxious Spin, And the Imperiled Future of STI Research
    By Richard Jefferys
  2. TAG at Ten: The Year 1997
  3. Marking Time: Commune of Shell Shocked Soldiers Springs Up Then Quickly Crumbles, Inexplicably
    By David Barr

October 2002
To read PDF, click here

  1. Double Jeopardy: Series of Superinfection Reports Leave Researchers Debating Not "If" but "How" -- And What It All Means
    By Richard Jefferys
  2. Re-Infection Data Summarized
    By Richard Jefferys
  3. The Way Forward: Philly ACT UPer and Health Gap Founder Tackles the Challenges of an Aging Activist Movement

September 2002
To read PDF, click here

  1. Turn the Beat Around: Disco Queen Née Policy Gadfly Recalls Decade of Seismic Shifts in Clinical Landscape
    By Lynda Dee
  2. TAG at 10: The Year 1996
  3. Putting It Together: As Scale Up to Rx for 3M by 2005 Proceeds, Activist Groups Worldwide Begin to Lay Groundwork
    By Mark Harrington

July 2002
To read PDF, click here

  1. Swindling Siam
    Consensus statement in opposition to licensure of Remune as monotherapy for HIV infection in Thailand
  2. Co-Conspirators
    HIV spread threatens decade's tuberculosis treatment/prevention success
  3. Guiding Light
    Overwhelming array of variables confounds interpretation of co-infection studies

May 2002
To read PDF, click here

  1. Fairy Tale Failure: Studies of PI-Resistant Virus Offer Tantalizing Possibilities for Immune Reconstitution
    By Richard Jeffreys
  2. Community Rx: Scrapping Volunteer Model Meant Curtains for Activist Conscripts and Paved Way for TAG Ascendency
    By David Barr
  3. TAG at 10: The Year 1995
  4. Advocate Finds Harrington's WHO Guideline Comments Refreshing
    By Richard Stern

April 2002
To read PDF, click here

  1. Flying the Coop: Giant Prophylactic Enshrouds Senator's Suburban Home; New Era of Inside/Outside Activism Is Born
  2. TAG at 10: The Year 1994
  3. Suivez La Piste: HIV-Specific CD4 Cell, Holy Grail of Immune Control, Is Hunted Down in Paris Laboratory
    By Richard Jefferys
  4. HIV-Specific T-Cell Activity by Fiat? Studies Currently Underway in France
  5. Not to Be Sneezed At: Merck's HIV Vaccine Program

March 2002
To read PDF, click here

  1. Activism = Hope: TAG Elder/Alumnus Remembers Struggles Past and Present With Humility, Nostalgia, Foreboding
    By Gregg Gonsalves
  2. Once We Were Warriors: Activist Corpses Borne in Protest, Furtive Legislative Coups, and the Devastation That Was Berlin
    By Mark Harrington
  3. TAG at 10: The Year 1993

January/February 2002
To read PDF, click here

  1. Annals of Crisis: A Peek Back at TAG's First Year Shows How Much, and How Little, Has Changed
    By Mark Harrington
  2. Revenge of the CTLs: Harvard Vaccine Team Exposes Potential Dark Side of Reliance on Cellular Immune Protection
    By Richard Jeffreys
  3. Mobilizing the Troops: Newly International North American Activist Alliance Gathers in Vancouver
    By Mark Baker


November 2001
To read PDF, click here

  1. Tenofovir (Viread), First Novel Antiviral Agent in Six Years, Approved by FDA
  2. Riddle Women: Reports of Progress Toward Understanding How Some People Appear to Fight Off HIV
    By Richard Jeffreys
  3. Studies on Exposed Seronegative Cohorts
  4. Patent Politics: Nongovernmental Organization Access Effort Dealt Stealth Blow By Ivy League Development Institute

September 2001
To read PDF, click here

  1. Breaking It Down
  2. Down the Pike: Argentina International AIDS Society Conference Snoozer Prompts Systematic Review of Drug Pipeline
    By Mark Harrington
  3. Shreds of Evidence: Shudda, Cudda, Wudda -- Reevaluating the Treatment Revolution After the Fall
    By David Barr
  4. Coming, Going and Gone: The Drug Development Pipeline, 2002

July/August 2001
To read PDF, click here

  1. Strike Two: Succumbing to Exhaustion
    By David Barr
  2. Drug Economy: Souped-Up Monotherapy
    By Mike Barr
  3. Human Leukocyte Antigens (HLA) and HIV Disease Progression

June 2001
To read PDF, click here

  1. Vaccine Vitriol: Call for Poor Country Focus on Treatment, Care Programs Elicits Voice of Concern from Vaccine Outfit
    By Mark Harrington
  2. African Epistle: Outrage, Indifference Greet Plans for Worldwide Treatment Agenda -- As Millions More Die
    By Mark Harringon
  3. Stalled in the Gates: The Not So Accelerated Access Initiative
    By Mark Harringon

April 2001
To read PDF, click here

  1. Needleless Retinitis Therapy With FDA Approval of Oral CMV Drug
  2. FDA Discusses Trial Design for Salvage Therapy
  3. Brazil 1, Merck 0: The Cost of Generic Drugs in Brazil

March 2001
To read PDF, click here

  1. Vaccine Advance: Merck Makes Surprise Announcement of Human Vaccine Trial, Currently Underway
  2. Open Letter to Pharma Execs
  3. March 5th: Day of Global Direct Action for Drug Access

January 2001

  1. Pendulum Swing: Treatment Paradigms Come and Go, But the Virus and Its Problematic Potions Appear Intractable
  2. Simian Success: Vaccine Study Seen as Significant Advance, But Questions Remain About Human Applicability
  3. Early Indications of What "The Accidental President" Might Do for AIDS


December 2000

  1. Brazil: What Went Right?
  2. Glaxo Guts Ghana's Import of Generic Combivir and Prepares for Battle
  3. Generic Jabberwocky: Quality Control of Brazilian-Made Antivirals

September 2000

  1. Being There: Durban Delegates Return Stateside, Fired Up and Ready to Jump Back Into the Fray
  2. African Justice: High Court Official, Openly HIV-Positive, Brings Durban Crowd to Their Feet With Heartfelt Plea for Equity
  3. Taking it to the Street: Thousands Strong, Fledgling South African Activist Group Sends Tremors Around the Globe
  4. While You Were Sleeping: An African AIDS Aid Chronology

August 2000

  1. All The Things You Are: Stephen Matthew Gendin, February 20, 1966 - July 19, 2000
  2. Call To Arms: Africa to Asia, Caribbean to Kazakhstan, An Explosive Epidemic Said to Threaten Backbone of Civil Society
  3. Dear Dr. Fauci: Broad Coalition of Organizations Calls on NIH to Devote Resources to Questions of Long-Term Therapy
  4. Notice Paid: TAG's Hepatitis Project Bears Its First and Future Fruit, Issues Research and Treatment Policy Recommendations
  5. Hepatitis C Infection Research & Policy Recommendations

July 2000

  1. Therapeutic Drug Monitoring in HIV Clinical Care
  2. What's This About P-Glycoprotein?
  3. P-gp and the Drugs It Affects
  4. Some Unanswered Questions About Therapeutic Drug Monitoring

June 2000

  1. Liver Spot: Progress Is Being Made But Much Remains to Be Done in the Treatment of Hepatitis C Infection
  2. Vagina Dialogues: Women-Controlled STD Prevention Methods Take Center Stage in Washington
  3. Striking the Balance: Brave New World of Human Gene Sequencing Finds Porous Policy Guidelines to Its Liking

April 2000

  1. Bonanza: With Demand for Treatment Breaks at Record Level, Market for Tiny, Uninterpretable Studies Flourishes
  2. Diminishing Returns: Two-Week Viral Rebounds in Four Swiss Intermittent Treatment Trial (SITT) Patients over the course of Three STIs (Table)
  3. Research Rut: Beefed Up Federal AIDS Vaccine Program Found to Suffer from Lingering Shortcomings
  4. Agouron and Immune Response to Bridge Rx Gap

March 2000

  1. Cohort Studies Suggesting Immediate HAART Confers No Extra Benefit Compared with Deferred HAART in HIV-Infected Persons CD4 >200 cells/mm3 (Table)
  2. Behemoth: Eradication's Ebb Finds Researchers Wrestling Again with Clinical Outcome Concerns
  3. ART Real World: Observational Databases Promise to Solve Clinical Trials Lag, But Experts Warn All Data Not Created Equal
  4. OCS Redux: International Statistical Panel Puts Observational Cohort Study Research Possibilities into Perspective, Identifies Limitations

January 2000

  1. Selected Primate Models of HIV Infection (Table)
  2. Research Agenda for Treatment Breaks
  3. Death by Rx: Where Good Meets Harm
  4. Vaccine Notes from the Cent Gardes


September 1999

  1. Not So Unforgiving After All? (Table)
  2. HIV Immunology: The Road Ahead
  3. Toronto: Stirrings of a Treatment Revolution
  4. Stopping Therapy: Intriguing New Data

June 1999

  1. Data Drought: As Treatment Euphoria Ebbs, Stubborn Uncertainties Resurface But Are Unlikely to Be Resolved
  2. Early or Late? Arguments for Immediate Antiretroviral Therapy Versus Delayed Antiretroviral Therapy (Table)
  3. Gotcha: HIV Antibody Breakthrough in Transgenic Mice Could Prove Boon to Vaccine Effort
  4. Status of Current HIV-1 Vaccine Strategies (Table)

May 1999

  1. TAG Community Forum: AIDS Vaccines and Microbicides, the Latest Developments
  2. AZT Monotherapy Veteran Checks out Chemotherapeutic Quitsville and Lives to Tell About It
  3. Frontiers of Immunology: Thymic Rebound, Naïve CD4+ T-Cell Repopulation Demonstrated in Individuals on HAART
  4. T-Cell Kinetics in HIV-Negative and HIV-Infected Individuals (Table)
  5. Differences Between Hellerstein and Ho T-Cell Labeling Experiments (Table)
  6. Thymic Immigration (Table)

March 1999

  1. Researchers and Patients Struggle to Interpret Viral Breakthrough
  2. Continual Suppression to Yield to Pulsed Therapy? (sidebar)
  3. AIDSVax Field Trial Makes a Splash While Humble Canarypox Phase II Plods Along Uncelebrated
  4. Status of Current HIV-1 Vaccine Strategies (Table)

January 1999

  1. Scottish Scribe Tells of Resistance Testing Success, Superinfection, Flaws in Dual Protease Regimens
  2. At a Glance: South Africa (Table)
  3. VIRADAPT: Physician Judgment vs. Genotypic Resistance Results for Treatment Switching Decisions Upon Virologic Rebound (Table)
  4. Tidy Clinical Science Stares Down Quotidien Chaos Theory; Might Not "Late, Hard" Be Better After All?


En Español

  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

See Also
Index of Articles From Treatment Action Group (TAG)